We have placed cookies on your computer to help make this website better. We use a Matomo Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by Matomo (e.g. deny use/opt-out).

Ok, continue to the website

Statements | Media | Grünenthal Group

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.

... Research & Development

For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient and the use of big data that result in innovative solutions for the patients need.

... Strategy

Our R&D pipeline is a source of great excitement – we currently have several new drug candidates and technologies in different phases of development.

... Pipeline

We aspire to solve pain, to do this we have to shape this therapeutic area. Building on our own R&D expertise, we aim to develop disease-modifying approaches, expand into new modalities, target significant unmet needs within niche disease areas, and apply our knowledge to develop our understanding of pain as a disease.

... Focus Pain

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Collaboration with the scientific community is central to our R&D strategy. Let’s work together – collaborate with us!

... Collaborate with us

We believe that success comes from close collaborations founded on a shared vision to develop innovative medicines for patients that suffer from diseases with high unmet needs.

... Partnering

We strengthen and develop our core markets Europe, North America, Latin America and Asia through acquisitions, asset deals, in-licensing, commercialization and distribution deals.

... Areas of interest

We use our resources and expertise to get funding that enables collaborative and cutting-edge pain research and then translate this to improved, real-world outcomes.

... Partnerships and collaborations

We work with the world’s biggest public-private partnership organisation in the life sciences as co-leaders of the latest pain initiative.

... Public Private Partnerships

Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!

... Jobs and career

From research scientists and high achieving graduates to experts in marketing and production, our open and inclusive culture helps everyone thrive.

... Meet our people

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Media Statements

2019

Media Statement Grünenthal

11/29/2019

Aktuelle Medienberichterstattung zur Conterganstiftung und Sedalis

Zur Zeit wird in den Medien berichtet, dass die Conterganstiftung beabsichtigt, die Zahlungen an brasilianische Betroffene, die durch das Produkt "Sedalis" geschädigt wurden, einzustellen. Wir nehmen wie folgt Stellung:

... More

11/29/2019

Media reports about the German Contergan Foundation and Sedalis

We have recorded numerous media reports about the intent of the German Contergan Foundation to cease payments to people affected by "Sedalis". Grünenthal's position on this matter is as follows:

... More

7/1/2019

Grünenthal to discontinue Phase III clinical trials of Neridronate in Complex Regional Pain Syndrome (CRPS)

Grünenthal decided to discontinue its two ongoing Phase III clinical trials of Neridronate (KF7013-02 and KF7013-04) in patients with Complex Regional Pain Syndrome (CRPS). The clinical development program had foreseen to randomize 360 people with CRPS in these trials.

... More

Štěpán Kráčala

Head Global Communications

Grünenthal GmbH

52099

Germany

Phone +49 241 569-1335

E-Mail Stepan.Kracala@grunenthal.com